While inflammation is a beneficial component of the body’s response to harmful stimuli, prolonged or excessive inflammation triggers a wide variety of diseases. Current anti-inflammatory drugs (steroids, NSAIDs and immune selective anti-inflammatory derivatives) have undesirable side effects and for many indications including dermatology, drugs that act by a novel MOA may be more efficacious.
Scientists at Scripps Institute of Oceanography have purified and validated the utility of honaucin A (from the cyanobacteria Leptolyngbya crossbyana) for dermatologic indications and other inflammatory conditions. The dual MOA vs. inflammation and bacterial infection make honaucins particularly interesting for diseases that are characterized by features of inflammation and infection. Synthesis of honaucin and numerous analogs enabled SAR analysis, which revealed essential structural features for activities of interest and provided analogs with greater potency in bio-assays that assess inhibition of inflammation.
US issued patent for “Anti-Inflammatory and Quorum Sensing Inhibition Compounds and Methods of Making and Using Them” available for exclusive licensure.
|United States Of America||Issued Patent||9,073,884||07/07/2015||2010-329|
dermatology, skin, psoriasis, trauma, inflammation, anti-bacterial, quorum-sensing inhibitor, quorum-sensing, inflammatory, surgical trauma, infection, biofilm, anti-biofilm, plaque, dental, anti-microbial, anti-bacterial, anti-fouling